Peptide Therapeutics Market

Global Peptide Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10348
Available Format:
Category : Biotechnology

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1. Market Segmentation by Route of Administration

1.3.2. Market Segmentation by Application

1.3.3. Market Segmentation by Marketing Type

1.3.4. Market Segmentation by Geography

1.3.5. Analysis Period

1.3.6. Market Data Reporting Unit

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents By region By industry participants By company type

2.3. Market Size Estimation

2.4. Market Breakdown and Data Triangulation

2.5. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1. Market Segmentation

4.1.1. Overview by Route of Administration Oral Route Parenteral route

4.1.2. Overview by Application Cancer Central nervous system Respiratory disorders Metabolic disorders Cardiovascular Infection Hematological disorders Gastrointestinal disorders Acromegaly Others

4.1.3. Overview by Marketing Type Branded peptide therapeutics Generic peptide therapeutics

4.2. Market Dynamics

4.2.1. Trends

4.2.2. Drivers Impact analysis of drivers on market forecast

4.2.3. Restraints Impact analysis of restraints on market forecast

4.2.4. Opportunities

4.3. Porter’s Five Forces Analysis

Chapter 5. Market Size and Forecast by Route of Administration

5.1. Oral Route

5.2. Parenteral Route

Chapter 6. Market Size and Forecast by Application

6.1. Cancer

6.2. Central Nervous System

6.3. Respiratory Disorders

6.4. Metabolic Disorders

6.5. Cardiovascular

6.6. Infection

6.7. Hematological Disorders

6.8. Gastrointestinal Disorders

6.9. Acromegaly

6.10. Others

Chapter 7. Market Size and Forecast by Marketing Type

7.1. Branded Peptide Therapeutics

7.2. Generic Peptide Therapeutics

Chapter 8. Market Size and Forecast by Geography

8.1. North America Peptide Therapeutics Market

8.1.1. By Route of Administration

8.1.2. By Application

8.1.3. By Marketing Type

8.1.4. By Country – The U.S and Canada

8.2. Europe Peptide Therapeutics Market

8.2.1. By Route of Administration

8.2.2. By Application

8.2.3. By Marketing Type

8.2.4. By Country –Germany, France, The U.K and rest of Europe

8.3. Asia-Pacific Peptide Therapeutics Market

8.3.1. By Route of Administration

8.3.2. By Application

8.3.3. By Marketing Type

8.3.4. By Country -China, Japan, India and Rest of Asia-Pacific

8.4. Latin America Peptide Therapeutics Market

8.4.1. By Route of Administration

8.4.2. By Application

8.4.3. By Marketing Type

8.4.4. By Country – Brazil, Mexico and Rest of Latin America

8.5. Middle East & Africa Peptide Therapeutics Market

8.5.1. By Route of Administration

8.5.2. By Application

8.5.3. By Marketing Type

Chapter 9. Competitive Landscape

9.1. Competitive Analysis of Key Players

9.2. Global Strategic Developments

Chapter 10. Company Profiles

10.1. Bachem Holding AG

10.1.1. Business Overview

10.1.2. Product and Service Offerings

10.1.3. Key Financial Summary

10.1.4. Strategic Growth Plan

10.2. Amgen, Inc.

10.2.1. Business Overview

10.2.2. Product and Service Offerings

10.2.3. Key Financial Summary

10.2.4. Strategic Growth Plan

10.3. AstraZeneca plc

10.3.1. Business Overview

10.3.2. Product and Service Offerings

10.3.3. Key Financial Summary

10.3.4. Strategic Growth Plan

10.4.  Merck & Co. Inc.

10.4.1. Business Overview

10.4.2. Product and Service Offerings

10.4.3. Key Financial Summary

10.4.4. Strategic Growth Plan

10.5.  Eli Lily and Company

10.5.1. Business Overview

10.5.2. Product and Service Offerings

10.5.3. Key Financial Summary

10.5.4. Strategic Growth Plan

10.6. CordenPharma International GmbH

10.6.1. Business Overview

10.6.2. Product and Service Offerings

10.6.3. Key Financial Summary

10.6.4. Strategic Growth Plan

10.7. Ipsen S.A.

10.7.1. Business Overview

10.7.2. Product and Service Offerings

10.7.3. Key Financial Summary

10.7.4. Strategic Growth Plan

10.8. Novartis AG

10.8.1. Business Overview

10.8.2. Product and Service Offerings

10.8.3. Key Financial Summary

10.8.4. Strategic Growth Plan

10.9.  PolyPeptide Group

10.9.1. Business Overview

10.9.2. Product and Service Offerings

10.9.3. Key Financial Summary

10.9.4. Strategic Growth Plan

10.10. F. Hoffmann-La Roche AG

10.10.1. Business Overview

10.10.2. Product and Service Offerings

10.10.3. Key Financial Summary

10.10.4. Strategic Growth Plan

10.11. Novo Nordisk A/S

10.11.1. Business Overview

10.11.2. Product and Service Offerings

10.11.3. Key Financial Summary

10.11.4. Strategic Growth Plan

10.12. Sanofi

10.12.1. Business Overview

10.12.2. Product and Service Offerings

10.12.3. Key Financial Summary

10.12.4. Strategic Growth Plan

10.13. Teva Pharmaceutical Industries Ltd.

10.13.1. Business Overview

10.13.2. Product and Service Offerings

10.13.3. Key Financial Summary

10.13.4. Strategic Growth Plan

*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.

Chapter 11. Appendix

11.1. Abbreviations

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry